NCT06511193View on ClinicalTrials.gov

Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]

RecruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

September 17, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

Budenoside/Glycopyrronium/Formoterol

Patients with COPD who initiate BGF as prescribed by physician per the approved country-specific label and reimbursement criteria

Trial Locations (1)

N8W 5V7

RECRUITING

Research Site, Windsor

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

Asthma Research Group Inc.

UNKNOWN

collaborator

University Health Network, Toronto

OTHER

lead

AstraZeneca

INDUSTRY